Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Inclusion Criteria:

• 18 years of age or older at screening

• Locally advanced (not amenable to curative surgery or radiation therapy) ormetastatic RCC with diagnosis confirmed by histology/cytology

• At least one measurable (as defined by the investigator) and untreated lesion

• Adequate hematologic, hepatic, cardiac and renal function

• No prior systemic therapy for RCC (immunotherapy after surgery is allowed ifreceived >12 months prior)

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

• All International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) basedrisk categories

Exclusion Criteria:

Participants may be excluded if they meet any of the following:

• Known active brain lesions including leptomeningeal metastasis, brainstem, meningealor spinal cord metastases or compression.

• Clinically significant risk of haemorrhage or fistula

• History of another malignancy within 3 years

• History of allogeneic organ transplantation and allogeneic hematopoietic stem celltransplantation.

• active autoimmune diseases requiring systemic treatment within the past 2 years

• uncontrolled cardiac and other comorbidities within 6 months prior to the first dose

• Major surgery or severe trauma within 4 weeks before the first dose, or plannedmajor surgery during the study

• History of severe bleeding tendency or coagulation dysfunction

• History of oesophageal varices, severe ulcers, gastrointestinal perforation,abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess

• Acute, chronic or symptomatic infections

• Participants with history of immunodeficiency